MoonLake Immunotherapeutics (MLTX) Notes Payables (2020 - 2022)

MoonLake Immunotherapeutics (MLTX) posted quarterly Notes Payables of $150000.0 for Q1 2022, down 99.0% quarter-over-quarter from $15.0 million in Q4 2021.

MoonLake Immunotherapeutics (MLTX) Notes Payables (2020 - 2022) Analysis & Trends

MoonLake Immunotherapeutics' Notes Payables history runs 3 years deep, the most recent figure standing at $150000.0 for Q1 2022.

  • In Q1 2022, Notes Payables changed N/A year-over-year to $150000.0; the TTM figure through Mar 2022 stood at $150000.0 (changed N/A YoY), while the FY2021 annual figure was $15.0 million, up 25734.01% from the prior year.
  • Notes Payables for Q1 2022 stood at $150000.0, down from $15.0 million in the prior quarter.
  • The five-year high for Notes Payables was $15.0 million in Q4 2021, with the low at $58063.0 in Q4 2020.
  • The 3-year median for Notes Payables is $150000.0 (2022), against an average of $5.1 million.
  • Peak annual rise in Notes Payables reached 25734.01% in 2021, while the deepest fall reached 25734.01% in 2021.
  • MoonLake Immunotherapeutics' Notes Payables stood at $58063.0 in 2020, then surged by 25734.01% to $15.0 million in 2021, then sank by 99.0% to $150000.0 in 2022.
  • Business Quant data shows MLTX's Notes Payables at $150000.0 in Q1 2022, $15.0 million in Q4 2021, and $58063.0 in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 MoonLake Immunotherapeutics 1.40 Bn 864.68 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2022 150,000.00
Dec 31, 2021 15.00 Mn
Dec 31, 2020 58,063.00